

ABSTRACT

The present invention is directed to methods for treating Alzheimer's Disease by modulating divalent cation, trivalent cation and/or heparin interaction with amyloid precursor protein (APP). In particular, the present invention is directed to methods for treating Alzheimer's Disease by administering to a patient with Alzheimer's Disease a therapeutically effective amount of a zinc binding agent for modulating the interaction of zinc and/or heparin with APP and thereby preventing the aberrant processing of APP.